Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria~1. Provision of signed and dated, written informed consent before any study-specific procedures.~2. Healthy male participants aged 18 to 45 years (inclusive) with suitable veins for cannulation or repeated venipuncture.~3. Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive and weigh at least 50 kg.~4. Participants is able to consume a low-fat meal within a 30-minute period.~5. Participants has a creatinine clearance (CRCL) greater than 50 mL/min using Cockcroft-Gault formula.~6. Participants is willing to comply with contraception requirements as described below:~   * Male participants with sexual partners who can become pregnant (i.e., women of childbearing potential) must use 2 highly-effective methods of contraception, one of which must be a barrier method (condom with spermicide) from the time of the first administration of the IMP until 12 weeks after the last administration of the IMP to avoid pregnancy and/or potential adverse effects on the developing embryo.~  * Participants with sexual partners who are pregnant must use an effective method of contraception (barrier method) from the time of the first administration of the IMP until 12 weeks after the last administration of the IMP.~  * Participants must avoid sperm donation during the study and for 12 weeks after the last administration of the IMP.~  * Reliable methods of contraception must be used consistently and correctly.~  * Reliable methods of contraception for participants include: Use of barrier methods (condom and spermicide) for the duration of the study until 12 weeks after the last administration of the IMP.~  * Acceptable methods for participants partners include:~     1. Use of implants, injectables and combined oral contraceptives (must be used in combination with a barrier method of contraception)~    2. Use of intrauterine devices (must be used in combination with a barrier method of contraception)~Exclusion Criteria :~1. Participants of Japanese, non-Japanese Asian or Indian ethnicity.~2. Participants has any one parent or grandparent (maternal or paternal) that was Japanese or non-Japanese Asian (e.g., China, Taiwan, Korea, Philippines, Thailand, Vietnam and Malaysia) or Indian.~3. History or presence of central serous retinopathy or retinal vein thrombosis, IOP greater than 21 mmHg or uncontrolled glaucoma.~4. History of any clinically significant disease or disorder which, in the opinion of the PI, may put the participant at risk because of participation in the study, influence the result of the study or influence the participants ability to participate in the study.~5. Participant has ophthalmologic conditions as follows:~   * Current or past history of central serous retinopathy/retinal pigment epithelial detachment or retinal vein occlusion.~  * Intra-ocular pressure \> 21 mmHg or uncontrolled glaucoma (irrespective of IOP).~6. Participant has any cardiac conditions as follows:~   * Uncontrolled hypertension (BP ≥ 150/95 mmHg despite medical therapy).~  * Acute coronary syndrome within 6 months before starting treatment.~  * Uncontrolled Angina - Canadian Cardiovascular Society grade II-IV despite medical therapy.~  * Symptomatic heart failure New York Heart Association (NYHA) Class II-IV, prior or current cardiomyopathy, or severe valvular heart disease.~  * Prior or current cardiomyopathy including but not limited to the following: 1) Known hypertrophic cardiomyopathy.~     2) Known arrhythmogenic right ventricular cardiomyopathy. 3) Previous moderate or severe impairment of LVEF \< 45% on echocardiography even if full recovery has occurred.~  * Left ventricular ejection fraction below the lower limit of normal (LLN) or \< 55% measured by ECHO at the Screening Visit.~  * Severe valvular heart disease.~  * Atrial fibrillation with a ventricular rate \> 100 beats per minute (bpm) on ECG at rest.~  * QTcF \> 450 ms or other factors that increase the risk of QT prolongation.~7. Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of IMP.~8. Any clinically relevant abnormal findings in physical examination, hematology, clinical chemistry, urinalysis, vital signs or ECG at the Screening Visit, which in the opinion of the PI, may put the participant at risk because of his participation in the study. Test may be repeated twice at the discretion of the Investigator if abnormal.~9. Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus (HIV) antibody.~10. A suspected/manifested infection according to the International Air Transport Association (IATA) Categories A and B infectious substances.~11. History of, or current alcohol or drug abuse, as judged by the principal investigator (PI).~12. Participation in another clinical study (investigational product administered within 30 days before the Screening Visit, or participation in a method development study \[no drug\] 30 days before the Screening Visit). Participation is defined as the completion of a treatment related visit.~13. Planned in-patient surgery, dental procedure or hospitalization during the study.~14. Plasma donation within 30 days of the Screening Visit or any blood donation/loss more than 500 mL during the 90 days before the Screening Visit.~15. A definite or suspected personal history of intolerance or hypersensitivity to drugs and/or their excipients, judged to be clinically relevant by the PI.~16. Known severe hypersensitivity to selumetinib or acetaminophen or any excipient of these medicinal products or history of allergic reactions attributed to compounds of similar chemical or biologic composition to selumetinib.~17. Current smokers or those who have smoked or used nicotine products (including e-cigarettes) within the 90 days before the Screening Visit.~18. Positive screen for drugs of abuse, alcohol or cotinine at the Screening Visit or on each admission to the Clinical Unit or positive screen for alcohol on each admission to the Clinical Unit.~19. Use of drugs with enzyme-inducing properties such as St John's Wort within 4 weeks before the first administration of IMP.~20. Use of any prescribed medicine and over-the-counter (OTC) drugs (including herbal remedies, vitamins and minerals) within 2 weeks or 5 times the half-life, whichever is the longer, of the respective drug before Day -1 or Treatment Period 1. No medications known to prolong the QT/QTc interval are allowed.~21. Excessive intake of caffeine-containing drinks or food e.g., coffee, tea, chocolate, Red Bull or cola (more than 6 units of caffeine per day). One caffeine unit is contained in the following items: 1 (6 oz) cup of coffee, 2 (12 oz) cans of cola, 1 (12 oz) cup of tea, ½ (4 oz) cup of energy drink (e.g., Red Bull) or 3 oz of chocolate.~22. Known or suspected history of alcohol or drug abuse or excessive intake of alcohol as judged by the PI.~23. Involvement of any AstraZeneca, PAREXEL or Clinical Unit employee or their close relatives.~24. Participants who have previously been randomized to treatment in the current study.~25. Judgment by the PI that the participant should not participate in the study if they have any ongoing or recent (i.e., during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions and requirements.~26. Vulnerable participants , e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Treatment Sequence 1 (Type: EXPERIMENTAL): Participants will receive Treatment A (selumetinib 25 mg granule, fasted state) in Part 1, Period 1, Treatment B (selumetinib 50 mg capsule, fasted state) in Part 1, Period 2, Treatment C (selumetinib 25 mg granule, fed state) in Part 2, Period 3, and Treatment D (selumetinib 50 mg capsule, fed state) in Part 2, Period 4. Participants will also receive a single 500 mg dose of acetaminophen at the same time as selumetinib administration where it will act as a marker for gastric emptying.
- Treatment Sequence 2 (Type: EXPERIMENTAL): Participants will receive Treatment B (selumetinib 50 mg capsule, fasted state) in Part 1, Period 1, Treatment A (selumetinib 25 mg granule, fasted state) in Part 1, Period 2, Treatment C (selumetinib 25 mg granule, fed state) in Part 2, Period 3 and Treatment D (selumetinib 50 mg capsule, fed state) in Part 2, Period 4. Participants will also receive a single 500 mg dose of acetaminophen at the same time as selumetinib administration where it will act as a marker for gastric emptying.
- Treatment Sequence 3 (Type: EXPERIMENTAL): Participants will receive Treatment A (selumetinib 25 mg granule, fasted state) in Part 1, Period 1, Treatment B (selumetinib 50 mg capsule, fasted state) in Part 1, Period 2, Treatment D (selumetinib 50 mg capsule, fed state) in Part 2, Period 3 and Treatment C (selumetinib 25 mg granule, fed state) in Part 2, Period 4. Participants will also receive a single 500 mg dose of acetaminophen at the same time as selumetinib administration where it will act as a marker for gastric emptying.
- Treatment Sequence 4 (Type: EXPERIMENTAL): Participants will receive Treatment B (selumetinib 50 mg capsule, fasted state) in Part 1, Period 1, Treatment A (selumetinib 25 mg granule, fasted state) in Part 1, Period 2, Treatment D (selumetinib 50 mg capsule, fed state) in Part 2, Period 3 and Treatment C (selumetinib 25 mg granule, fed state) in Part 2, Period 4. Participants will also receive a single 500 mg dose of acetaminophen at the same time as selumetinib administration where it will act as a marker for gastric emptying.

Based on this trial design, predict the completion outcome and termination type (if applicable).